But I know of one tiny company – Eyecarrot Innovations Corp. (TSX.V: EYC, OTC: EYCCF) – that is quietly attracting big name investors with a disruptive platform that’s never been seen before.
In fact, their state-of-the-art technology could be the missing key in tackling a national health epidemic that is threatening to reach crisis levels.
But don’t just take my word for it…
Fabrice Taylor — an analyst on BNN Bloomberg and publisher of one of the largest financial newsletters in Canada — thinks so too. He sees sales ramping-up in the coming months… and is so impressed with it he recently talked about it on national tv. 1
And when Fabrice buys a stock — much less talks about how much he likes it on tv — you should pay attention. His track record speaks for itself…
- Lithium X Energy: soared 387.8% after he recommended it
- New Flyer Industries: shot up 52%
- Canadian Natural Resources: rose 16%
- Centric Health Corporation: ran up 65%
- And FSD Pharma: blasted 400% higher
As you can see, Fabrice has a “sixth sense” when it comes to picking winners. And now he’s putting his money where his mouth is… taking a position in Eyecarrot.
But you know what?
He’s not the only big name interested in med-tech.
Some of the world’s richest men are taking up big positions in the industry too…
Billionaires Are Investing MILLIONS Into Med-Tech
Four of the world’s richest men are making BIG bets med-tech companies are headed higher:
- Ken Fisher — $3.1 billion net worth
He owns more than $50 million worth of med-tech stocks and has been adding to his positions… buying MDT and ABT in recent quarters.
- Ron Baron — $2.1 billion net worth
Ron is loading up on EW, ALGN, TFX, CMD with big purchases in the last few months
- Mario Gabelli — $1.6 billion net worth
Another billionaire, Gabelli recently topped-up his coffers with more than $5 million worth of ALGN and XRAY
- Joel Greenblatt — $500 million net worth
He recently bought BAX, RMD, doubled his position in MDT, and more than TRIPLED his position in STE
But while these wizards of Wall Street position themselves to profit with the usual suspects like MedTech and Align Technology, I think Eyecarrot Innovations (TSX.V: EYC, OTC: EYCCF) could become one of the biggest stories of 2019.
Read on to find out more…
I’m about to take you to the frontlines of the red-hot med-tech industry — where the smart money is piling in… and a little-known breakthrough may have set the stage for a tiny company named Eyecarrot Innovations Corp. (TSX.V: EYC, OTC: EYCCF) to experience huge growth in 2019.
For those of you who already own Eyecarrot Innovations, I have two words for you: well done.
If things go as well as I think, Eyecarrot is about to see their sales surge… and could be looking at a record year.
$76.5 Billion Brain Trauma Epidemic Reaches Crisis Levels… And Eyecarrot Has A Solution
Eyecarrot has developed a breakthrough treatment that could revolutionize a relatively untapped industry: concussion therapy.
Now I’m sure you’ve heard about the NFL settling a record $1 billion lawsuit with former players over concussion-related injuries.
But that’s peanuts. A little-known fact is that brain injuries rival cancer treatments with some of the highest costs in healthcare today…
In fact, 2.8 million people are rushed to emergency rooms and hospitals with a traumatic brain injury (TBI) each year — up to 90% of which are concussions. 45 That’s the same as the number of new heart attacks, strokes AND new cancer cases in the United States… combined. 678
TBI-related emergency room visits are also way up. They’ve increased 47% between 2007 and 2013, and have more than doubled for sports-related incidents.
What’s worse, concussion symptoms are still present in up to 78% of people 3 months after the injury. 35% percent — or as many as 880,000 — still feel the effects one year later. 10
It’s a massive burden on society. In fact, the economic costs of concussions and more severe traumatic brain injuries are estimated at an astounding $76.5 billion every year 11 — more than the entire economic outputs of Alaska, South Dakota, and Montana.
Now Here’s Where It Gets Interesting…
Up to 90% of people who have a concussion suffer at least some form of visual dysfunction. 12
That means millions of Americans have post-concussion symptoms such as blurred/double vision, visual and spatial field defects, light sensitivity, and focusing/tracking issues.
What’s more, there is no “standard therapy” to treat concussions.
Most doctors just recommend rest — meanwhile visual dysfunctions and other symptoms like headaches, memory loss, photosensitivity, confusion, and trouble focusing persist for weeks… months… even years.
That’s where Eyecarrot (TSX.V: EYC, OTC: EYCCF) comes in.
Eyecarrot has pioneered “Binovi”, a state-of-the-art platform that could change the way we treat TBI’s.
Binovi is a combination of specialized hardware and cloud-based software that allows doctors, therapists and optometrists to provide personalized treatment to patients in-office or at home.
Eyecarrot Makes Two Major Acquisitions To Develop Binovi
To develop the Binovi platform, Eyecarrot did more than just bring on board industry leaders like neuro-optometrist Dr. Selwyn Super. They went out acquired patents related to various products used to monitor and correct brain-to-eye problems.
They also acquired Wayne Engineering — the company that invented the Saccadic Fixator, a globally-recognized industry standard for monitoring various visual system functions. 13
Armed with these tools, Eyecarrot (TSX.V: EYC, OTC: EYCCF) developed a next-generation, state-of-the-art platform that is revolutionizing visual therapy and could change concussion treatment forever.
At the heart of it is the Binovi Touch.
This unique piece of hardware is known as a next generation saccadic system and it works by targeting a patient’s oculomotor sensory system — the same system the brain uses to makes sense of what, where, and when we see.
You see, half of all neural connections in the human brain — including cortical, subcortical, cerebellar, and brainstem networks — are involved in visual function. 14
By actively targeting the oculomotor system, Eyecarrot’s state-of-the-art diagnostic and treatment solution triggers neurons across multiple networks and forces them to work together.
This neural firing effectively helps repair and rebuild pathways that were damaged by blows to the head.
It could be the next big thing in brain trauma treatment.
Another Eyecarrot Innovation: A First-To-Market App That Makes Long-Term Treatment A Breeze
Eyecarrot also addresses another big void in concussion therapy: follow-up care.
The University of California San Francisco found that more than half of all people who suffer a concussion fail to see a doctor for a follow-up exam within 3 months. 16
But Binovi has a solution that makes follow-up treatment a breeze.
Part of the platform is an industry-first mobile app which enables doctors to recommend therapy without the need of an in-office visit.
The app also tracks what exercises have been done and the progress that has been made, providing valuable data back to the doctor or optometrist for further recommendations.
It’s the modernization breakthrough the concussion industry has been waiting for.
Binovi Could Revolutionize Trauma Treatment
Unlike medications or prescriptions that just mask the symptoms, Eyecarrot’s technology helps treat the underlying problem by targeting brain connections through the visual system.
The platform can help reduce or eliminate things like headaches, fatigue, irritability, photosensitivity, and confusion.
It can also improve memory, concentration, and balance — not to mention the more than 20 different visual skills affected by TBIs.
It’s like hitting ten birds with one stone.
That’s why concussion sufferers who use specialized visual therapy like Binovi are likely to recover more quickly and get back to their normal lives faster after their injuries.
Just ask Bryce Salvador, former NHL hockey player and Captain of the New Jersey Devils.
Bryce was hit in the head by a slapshot in 2010 and suffered a cochlear concussion. For more than a year he lived with severe dizziness, photosensitivity, balance problems, and sight issues. He says vision therapy played a crucial role in his recovery and was vital to his return to NHL hockey.
In fact, Bryce is such a believer in Binovi’s vision therapy that he recently joined Eyecarrot as a Special Advisor.
“After a cochlear concussion had left me sidelined for an entire hockey season, vision therapy along with sports vision training alleviated my visual symptoms and played a crucial role in my return to playing hockey in the NHL.”
For athletes like Bryce, Eyecarrot’s technology is a gamechanger – especially when untreated concussions can lead to severe and damaging health problems down the road…
Concussions And Degenerative Brain Disorders Like Dementia And Parkinson’s
Multiple studies have linked TBI’s to degenerative brain conditions like dementia, multiple sclerosis, Parkinson’s, and even suicide.
- University of California, San Francisco: Concussions Lead to Increased Dementia Risk in Older Adults — subjects were 42% more likely to get dementia after experiencing a TBI . 17
- Örebro University: teenagers who experience a concussion face an elevated risk of developing multiple sclerosis by up to 133%. 18
- UCSF: Study finds concussions cause 56% increased risk of Parkinson’s disease. 19
- University of Toronto: Study shows concussions linked to increased risk of suicide. 20
Not to mention all the headlines surrounding the NFL and chronic traumatic encephalopathy (CTE)…
- “N.F.L. Agrees to Settle Concussion Suit for $765 Million” — NY Times
- “Chronic traumatic encephalopathy found in 99% of studied brains from deceased NFL players” — CNN
- “CTE Is Found in an Ex-Giant Tyler Sash, Who Died at 27” — NY Times
Without a doubt, concussions are a HUGE health problem and treating them could lead to a tremendous growth opportunity for Eyecarrot (TSX.V: EYC, OTC: EYCCF).
But if you still don’t believe me, take a look at this…
Congress And The CDC Are Sounding Alarms…
The Center for Disease Control recently released reports stating TBIs and concussions are a major health concern in the United States, especially for the youth. They’ve even named it a “silent epidemic” because symptoms are not visible but can last a lifetime. 21
Just last month Congress passed the Traumatic Brain Injury (TBI) Reauthorization Act of 2018.
It provides $115 million to programs that will help the nation understand, respond to, and prevent brain injury. It also provides funding to the CDC to launch a National Concussion Surveillance System – an initiative to fill longstanding data gaps and provide a better estimate of the TBI burden.
Is Eyecarrot’s Therapy The Closest Thing To A Cure?
You see, there is no “magic pill” to help the concussion victims each year.
All clinical trials of experimental drugs have ended in disappointment, or still require years of testing:
- Progesterone, a hormone given to people immediately after acute traumatic brain injuries, showed the most promise in two 2014 studies. But late-stage results crashed, with infusions showing they were no more effective than a placebo.
- Astrocyte, is working on a compound that invigorates caretaker cells in the brain to help repair cells and reduce swelling. But early-stage clinical trials in people are not expected until 2020.
- Oxeia is aiming to begin mid-stage trials in humans of ghrelin – which is a naturally occurring peptide hormone that has neuroprotective properties. However, the company is still trying to raise $3 million in investments to begin their study.
Meanwhile, Eyecarrot’s proprietary platform is already finding success and could continue to gain traction in the market this year…
Big Deals And Big Partnerships To Drive Revenue Growth
Eyecarrot’s (TSX.V: EYC, OTC: EYCCF) growth could be about to take off. Not only is it signing big distribution deals, but it’s also expanding internationally:
- They recently announced a deal with Bernell, the largest distributor of vision therapy products in North America, to distribute 1,000 Binovi touch units… which could bring in $3 million in sales right there.
- They’ve partnered with UC Berkeley, the State University of New York, and Florida State University. Not only does this extend the reach of the Binovi Touch platform, it proves they’re on the cutting edge of concussion therapy and gives a huge credibility boost.
- And they recently signed deals with distributors in Australia, Asia, and Europe that will likely boost sales for months, even years ahead.
But here’s the best part…
The Binovi platform can be used to treat more than just TBIs.
It could also play a major role in areas such as education, personal fitness, healthy aging, as well as vestibular disorders and even neurocognitive disorders.
Not Just Concussions! 5 More Conditions Eyecarrot’s Technology Treats
It’s not just concussion victims Eyecarrot can help.
The Binovi platform’s specialized visual training can also improve symptoms of other conditions as well…
- ADD/ADHD misdiagnosis: 1.6 million children
Children with vision problems are twice as likely to be diagnosed with ADD/ADHD — and sadly, as many as 1.6 million may be misdiagnosed
- Strabismus or “cross eyes”: 1.2 million
There are over one million strabismus surgeries a year — many that could be avoided with training instead
- Amblyopia or “lazy eye”: 6–9 million
Another condition visual training can help. This is where one eye does not coordinate and track well with the brain
- Convergence insufficiency: up to 40 million
This disorder causes near vision problems and is often mistaken for dyslexia. It affects 2.5% to 13% of total population
- Healthy Aging: 36 million
Our eyes changes as we age but consist visual training can help – especially for the 36 million drivers over 65
These are all areas where this groundbreaking technology can have a big potential impact and could easily translate into rapid scaling and growth for the company.
Listen, Eyecarrot (TSX.V: EYC, OTC: EYCCF) is lining up to be one of the biggest stories of 2019.
What’s more, the timing couldn’t be better…
Med-Tech Shares Are Surging Higher
Medical device stocks are hot right now. Unlike the Dow Jones or NASDAQ, share prices are climbing higher:
Dexcom: up 157.6%
Its flagship device is the G6 continuous glucose monitor
Abiomed: up 47.9%
Its flagship device is the Impella heart pump
Haemonetics Corporation: up 53.8%
Its flagship device is blood collection device
Atricure: up 73.5%
Its flagship device is the Isolator Synergy Ablation System
Integer Holdings: up 65.1%
Integer is a medical device contract manufacturer and makes a variety of devices
And NovoCure Limited: up 117%
Its flagship device is a wearable electronic field generator and transducer arrays for cancer patients
In fact, the iShares US Medical Device ETF (IHI) which holds 59 different stocks (so you know it’s an excellent measure of industry performance) has outperformed the Dow nearly THREE-FOLD in the past 12 months.
It’s up 12.83%. Meanwhile, the Dow is down 7.63%. The S&P 500 lost 7.5%. And the NASDAQ fell 6.18%.
It’s Time To Make Your Move
Listen, I’ve researched dozens of small companies but it’s rare to find one with this much upside.
- Eyecarrot has developed a breakthrough technology
- It could revolutionize a $76.5 billion market
- It’s already seeing tremendous success — with professional athletes raving about it
- Orders are coming in… and sales could soon surge
Not to mention, med-tech stocks are red-hot…
Billionaires like Ken Fisher are moving in…
And Fabrice Taylor, BNN Bloomberg analyst and publisher of one of the largest financial newsletters in Canada already bought the stock.
ATTENTION: Fabrice Taylor Likes Eyecarrot (TSX.V: EYC, OTC: EYCCF)
Look… when I discover a company with this sort of growth potential, I’m usually prepared to accept some downside.
But while all small med-tech stocks have risk, Eyecarrot Innovations has one of the most favorable outlooks I’ve ever seen.
I mean, it doesn’t take a rocket scientist to figure out that if a respected investor like Fabrice Taylor publicly declares that he likes a stock– and bought it — then you should pay attention.
Of course, I urge you to continue doing research. Proper due diligence before investing is always wise.
But if this is your kind of play, then do yourself a favor and take a look at Eyecarrot Innovations Corp. (TSX.V: EYC, OTC: EYCCF) right now.
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT. This communication is a paid advertisement. ARUGlobalInc.com, ARU Global, Inc., and their owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been paid by Eyecarrot Innovations Corp. to conduct investor awareness, advertising and marketing. Since May 2018, Eyecarrot has paid the Publisher approximately $773,000 and has an agreement to pay an additional $500,000 for the Publisher’s advertising and marketing services including expenses associated with the creation, publication and distribution of this communication. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third party, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher does not own any interest in Eyecarrot Innovations Corp. or its securities and does not have any right or intent to acquire such an interest. The Publisher is informed that a writer contracted to work on this communication owns warrants to purchase 65,000 shares of Eyecarrot common stock at an exercise price of $0.30. Stock ownership is an additional reason why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to
differ include, but are not limited to, changing governmental laws and policies, the success of the companies’ technology, the success of the companies’ drilling excursions, the size and growth of the market for the companies’ products and services, the companies’ ability to fund their capital requirements in the near term and long term, pricing pressures, etc.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. ARUGlobalInc.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.